Drugs / [²¹²Pb]Pb-ADVC001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05720130 | Mar 2023 → Jan 2029 expected | prostate carcinoma | AdvanCell Pty Limited | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [²¹²Pb]Pb-ADVC001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05720130 ↗ |
| Known as | ADVC001 | “All participants are randomized 1:1 to receive either 160 or 200 MBq of ADVC001.” NCT05720130 ↗ |
| Route | Intravenous | “administered intravenously” NCT05720130 ↗ |